Fractyl Health (NASDAQ:GUTS) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Fractyl Health (NASDAQ:GUTS) from a hold rating to a sell rating in a report issued on Saturday morning.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Craig Hallum assumed coverage on shares of Fractyl Health in a research note on Wednesday, July 1st. They set a “buy” rating and a $4.00 target price on the stock. Finally, Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.12.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $0.68 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 3.15. The stock’s fifty day moving average is $0.76 and its two-hundred day moving average is $0.67. The firm has a market capitalization of $108.24 million, a P/E ratio of -0.77 and a beta of 2.32. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $2.44.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Monday, August 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. On average, research analysts anticipate that Fractyl Health will post -0.53 earnings per share for the current year.

Insider Buying and Selling at Fractyl Health

In other news, Director Ian Sheffield acquired 35,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the acquisition, the director owned 35,000 shares of the company’s stock, valued at $25,550. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William Bradley bought 68,493 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the purchase, the director owned 84,622 shares in the company, valued at $61,774.06. This represents a 424.66% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 171,493 shares of company stock valued at $127,150. Company insiders own 8.52% of the company’s stock.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors have recently bought and sold shares of GUTS. Sanctuary Advisors LLC purchased a new stake in Fractyl Health during the second quarter worth about $26,000. Jane Street Group LLC purchased a new position in shares of Fractyl Health in the second quarter valued at approximately $31,000. Accredited Investors Inc. purchased a new position in shares of Fractyl Health in the first quarter valued at approximately $46,000. Scientech Research LLC purchased a new position in shares of Fractyl Health in the third quarter valued at approximately $49,000. Finally, FNY Investment Advisers LLC grew its holdings in shares of Fractyl Health by 84.3% in the second quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock valued at $51,000 after purchasing an additional 29,920 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.